Nanobiosym, a leading nanotechnology firm, said that Mr Ratan Tata, Chairman of the multibillion-dollar global conglomerate Tata Group, has joined the firm’s global advisory board.

Nanobiosym and its commercial engine Nanobiosym Diagnostics create and commercialize breakthrough technologies at the nexus of physics, biomedicine, and nanotechnology.

“I am honored to welcome Mr Tata to our global advisory board,” said Nanobiosym Chairman and CEO, Dr Anita Goel, a Harvard and MIT-trained physicist and physician. “I am inspired by his example, which provides us with a practical roadmap for bringing cutting edge technologies into emerging global economies and extending our reach to broad markets at the ‘bottom of the pyramid’.”

Nanobiosym has developed Gene-RADAR, a portable nanotechnology platform that rapidly and accurately detects genetic fingerprints from any biological organism. Dr Goel’s vision is to give patients worldwide real-time access to their own diagnostic information through low-cost handheld devices that could detect disease from a single drop of blood or saliva.

“Nanotechnology has the potential to revolutionize the way we tackle key issues facing the world today, and Nanobiosym is working at the forefront of this revolution,” Mr Tata said. “Dr Goel has forged a bold model for driving technological innovation and commercialization, while maximizing global humanitarian impact. I am delighted to join the Nanobiosym global advisory board, and I look forward to working closely with D Goel and her team.”

Mr Alfred Ford, Director of the Ford Motor Company Fund and also a member of the Nanobiosym global advisory board, said, “Behind this vision is game-changing technology which can revolutionize healthcare globally. In the face of growing world health crises and transnational epidemics, Dr Goel and Nanobiosym are redefining the rules in the battle to diagnose disease and save lives.”